DYNAVAX TECHNOLOGIES CORP (44)

Browse by Contract Category

Contracts

Letter Agreement No. 2, dated October 31, 2022, by and among the Company, Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (Filed With SEC on November 3, 2022)
Amendment No. 2 to Supply Agreement, dated effective as of September 30, 2022, by and between the Company and Biological E. Limited (Filed With SEC on November 3, 2022)
Description of Capital Stock (Filed With SEC on February 28, 2022)
Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2022)
Commercial Lease Agreement dated September 13, 2021 by and between Onyx Dsseldorf S. r.l. and Dynavax GmbH (Filed With SEC on November 4, 2021)
Letter Agreement, dated August 30, 2022, by and among the Company, Zhejiang Clover Biopharmaceuticals, Inc., Clover Biopharmaceuticals (Hong Kong) Co., Limited and Sichuan Clover... (Filed With SEC on November 3, 2022)
Amendment No. 1 to Supply Agreement, dated effective as of June 23, 2022, by and between the Company and Biological E. Limited (Filed With SEC on November 3, 2022)
Letter Agreement, dated October 29, 2021, by and among the Company, Valneva Scotland Limited and Valneva Austria GmbH (Filed With SEC on February 28, 2022)
Restricted Stock Unit Award Agreement for Directors under the 2018 Equity Incentive Plan (Filed With SEC on February 28, 2022)
First Amendment to Commercial Manufacturing and Supply Agreement dated September 10, 2021 by and between Baxter Pharmaceutical Solutions LLC and Dynavax Technologies Corporation (Filed With SEC on November 4, 2021)
Supply Agreement dated July 1, 2021 by and between Company and Biological E. Limited (Filed With SEC on August 4, 2021)
Supply Agreement dated June 29, 2021 by and among Company, Zhejiang Clover Biopharmaceuticals, Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited (Filed With SEC on August 4, 2021)
Amended and Restated Dynavax Technologies Corporation 2021 Inducement Award Plan (Filed With SEC on August 4, 2021)
Amendment No. 5 to Term Loan Agreement and Fee Letter, dated May 3, 2021, by and among Company, CRG Partners III L.P., CRG Partners III-Parallel Fund A L.P. and CRG Servicing LLC (Filed With SEC on August 4, 2021)
First Amendment to Agreement, dated May 3, 2021, between the Company and Coalition for Epidemic Preparedness Innovations (Filed With SEC on August 4, 2021)
Form of Confirmation for Capped Call Transactions (Filed With SEC on May 13, 2021)
Indenture, dated as of May 13, 2021, by and between Dynavax Technologies Corporation and U.S. Bank National Association, as Trustee (Filed With SEC on May 13, 2021)
Description of Capital Stock (Filed With SEC on February 25, 2021)
Kelly MacDonald Employment Letter (Filed With SEC on February 25, 2021)
Amendment No. 4 to Term Loan Agreement and Fee Letter, dated January 29, 2021, by and among Company, CRG Partners III L.P., CRG Partners III-Parallel Fund A L.P. and CRG Servicing... (Filed With SEC on February 25, 2021)
Agreement, dated January 29, 2021 between Company and Coalition for Epidemic Preparedness Innovations (Filed With SEC on February 25, 2021)
Dynavax Technologies Corporation 2021 Inducement Award Plan, Form of Stock Option Grant Notice, Option Agreement, Form of Restricted Stock Grant Notice and Restricted Stock Unit... (Filed With SEC on January 12, 2021)
Amendment No. 3 to Term Loan Agreement and Fee Letter, dated November 2, 2020, by and among Company, CRG Partners III L.P., CRG Partners III-Parallel Fund A L.P. and CRG Servicing... (Filed With SEC on November 5, 2020)
Amended and Restated Management Continuity and Severance Agreement, dated September 22, 2020, between Michael S. Ostrach and the Company (Filed With SEC on November 5, 2020)
Supply Agreement, dated September 11, 2020, by and among the Company, Valneva Scotland Limited and Valneva Austria GmbH (Filed With SEC on November 5, 2020)
Sales Agreement, dated August 6, 2020, between the Company and Cowen and Company, LLC (Filed With SEC on August 6, 2020)
Amended and Restated 2004 Non-Employee Director Equity Program and Amended and Restated 2005 Non-Employee Director Cash Compensation Program, as amended (Filed With SEC on August 6, 2020)
Amended and Restated 2018 Equity Incentive Plan (Filed With SEC on August 6, 2020)
Underwriting Agreement, dated May 21, 2020, by and among Dynavax Technologies Corporation, Cowen and Company, LLC, Evercore Group L.L.C. and William Blair & Company, L.L.C., as... (Filed With SEC on May 22, 2020)
Chief Executive Officer Letter, dated December 13, 2019, between the Company and Ryan Spencer (Filed With SEC on March 11, 2020)
Description of Capital Stock (Filed With SEC on March 11, 2020)
Dynavax Technologies Corporation U.S. Annual Bonus Plan (Filed With SEC on March 11, 2020)
President and Chief Operating Officer Letter, dated December 13, 2019, between the Company and David Novak (Filed With SEC on March 11, 2020)
Sublease, by and between Dynavax Technologies Corporation and Zymergen Inc., dated July 12, 2019 (Filed With SEC on November 7, 2019)
Form of Series B Preferred Stock Certificate (Filed With SEC on November 7, 2019)
Amendment No. 2 to Term Loan Agreement and Fee Letter, by and among Dynavax Technologies Corporation, CRG Partners III L.P., CRG Partners IIIParallel Fund A L.P. and CRG Servicing... (Filed With SEC on November 7, 2019)
Sublease, by and between Dynavax Technologies Corporation and MedAmerica, Inc. (d/b/a Vituity), dated July 2, 2019 (Filed With SEC on November 7, 2019)
Form of Indemnification Agreement (Filed With SEC on November 7, 2019)
Form of Warrant to Purchase Common Stock (Filed With SEC on August 8, 2019)
Underwriting Agreement, dated April 7, 2019, by and among Dynavax Technologies Corporation, Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the... (Filed With SEC on August 8, 2019)
Co-President Officer Letter, dated May 30, 2019, between the Company and David Novack (Filed With SEC on August 7, 2019)
Form of Amended and Restated Management Continuity and Severance Agreement between the Company and certain of its executive officers (Filed With SEC on August 7, 2019)
Co-President Officer Letter, dated May 30, 2019, between the Company and Ryan Spencer (Filed With SEC on August 7, 2019)
Amended and Restated 2018 Equity Incentive Plan (Filed With SEC on August 7, 2019)